23ANDME HOLDING CO -CLASS A (ME)

US90138Q1085 - Common Stock

2.08  +0.04 (+1.96%)

After market: 2.07 -0.01 (-0.48%)

News Image
4 days ago - Seeking Alpha

23andMe GAAP EPS of -$0.14 beats by $0.04, revenue of $92.4M beats by $4M (NASDAQ:ME)

23andMe press release (NASDAQ:ME): Q4 GAAP EPS of -$0.14 beats by $0.04.Revenue of $92.4M (-8.1% Y/Y) beats by $4M.

News Image
4 days ago - 23andMe, Inc.

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN...

News Image
6 days ago - The Motley Fool

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

Neither has a traditional business model, but that could be an asset for both.

News Image
10 days ago - The Motley Fool

3 Key Biotech Trends for 2023 And Beyond

New opportunities are becoming apparent, but so are fresh risks in the biotech field.

News Image
10 days ago - InvestorPlace

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.

Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.

News Image
13 days ago - 23andMe, Inc.

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their...

News Image
14 days ago - InvestorPlace

3 Personalized Medicine Stocks to Buy for Long-Time Returns

Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.

News Image
18 days ago - 23andMe Holding Co.

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...

News Image
20 days ago - 23andMe Holding Co.

23andMe Releases New Report Revealing Likelihood of Developing Lupus

23andMe+ members can now gain insights on the chronic autoimmune condition

News Image
20 days ago - 23andMe Holding Co.

23andMe Releases New Report Revealing Likelihood of Developing Lupus

23andMe+ members can now gain insights on the chronic autoimmune condition...

News Image
21 days ago - 23andMe Holding Co.

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy

News Image
a month ago - 23andMe Holding Co.

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with...

News Image
2 months ago - 23andMe Holding Co.

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell...

News Image
2 months ago - 23andMe Holding Co.

23andMe Publishes Inaugural Environmental, Social and Governance Report

/PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access,...

News Image
2 months ago - 23andMe Holding Co.

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers

News Image
2 months ago - 23andMe Holding Co.

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers...

News Image
2 months ago - The Motley Fool

3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks

Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.

News Image
3 months ago - 23andMe Holding Co.

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented

News Image
3 months ago - 23andMe Holding Co.

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented...

News Image
3 months ago - The Motley Fool

AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023

They've been using machine learning for years, and now they might do even more.

News Image
3 months ago - 23andMe Holding Co.

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could...

News Image
3 months ago - The Motley Fool

2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise

There's nothing better than getting a bargain that'll pay off for years.

News Image
3 months ago - Bloomberg

Asia’s Richest Man Mukesh Ambani to Foray Into Genome Testing with $145 Kit

Mukesh Ambani's Reliance is seeking to disrupt DNA testing with $145 genome sequencing kits — undercutting rivals charging $1,000

News Image
3 months ago - The Motley Fool

2 High-Growth Stocks That Could Double Your Money in 5 Years or Less

Both are likely to double quite soon, and they aren't even that risky.

News Image
3 months ago - 23andMe Holding Co.

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610

News Image
3 months ago - 23andMe Holding Co.

23andMe to Present at Upcoming Investor Conferences

News Image
3 months ago - 23andMe Holding Co.

23andMe to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...

News Image
4 months ago - The Motley Fool

This Genetics Stock Could Have Massive Long-Term Potential

This healthcare company isn't without risk but is doing a good job executing on its vision.